| Previous Close | 0.9000 |
| Open | 0.8600 |
| Bid | 0.8500 x 0 |
| Ask | 0.9100 x 0 |
| Day's Range | 0.8300 - 0.8600 |
| 52 Week Range | 0.2500 - 1.6000 |
| Volume | 26,220 |
| Avg. Volume | 46,867 |
| Market Cap | 119.963M |
| Beta (5Y Monthly) | -0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0550 |
| Earnings Date | Mar. 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.10 |
- ACCESSWIRE
Helix BioPharma Corp. Extends Period to Exercise Warrants
RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.
- ACCESSWIRE
Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.
- ACCESSWIRE
Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board
RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr.
